RNKp30 monoclonal antibodies were generated by immunizing BALB/c mice with rNKp30-Fc fusion protein. The rNKp30-Fc fusion protein is a soluble protein consisting of the extracellular domain of rNKp30 fused to the Fc domain of human IgG1.
Cancers including breast, lung, colon and prostate account for almost ten million deaths worldwide every year. The main cause of cancer deaths is metastasis, which is the propensity of cancer cells to spread throughout the body.
Lab Designation: RB6 8C5; A rat-mouse hybridoma cell line producing a monoclonal IgG2b rat AB which recognizes most, if not all, granuloytes and granolucyte precursors in the mouse bone marrow.
The invention consists of the ability to treat inflammatory and autoimmune disorders, particularly but not exclusively those involving mucosal sites such as in the chronic inflammatory bowel disease, by blocking or altering 4B7 interactions with vascular and extracellular matr
Researchers in Prof. Mark Kay's laboratory have continued to develop novel recombinant adeno-associated viral (AAV) capsids via capsid gene shuffling that transduce human hepatocytes at high efficiency in vivo.
Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.
Heart rhythm disorders are difficult to treat with conventional drug therapy and intraoperative injury to the cardiac conduction system (CCS) complicates heart-related surgeries and is a major cause of morbidity and mortality.
Researchers in the Wyss-Coray Lab are investigating a potential therapeutic antibody to treat lysosomal storage disorders and other related neurodegenerative diseases.
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health.
Researchers at Stanford University have discovered that donor-specific anti-HLA antibodies can be used to detect and treat graft-versus-host disease (GVHD) in transplant recipients after allogenic transplantation.
Stanford scientists have developed cross-reactive antibodies that can bind human and murine NKp46 on NK cells and induce cytotoxicity and proliferation.